PARP plus ARSI improves rPFS in HRR-altered metastatic prostate cancer, with larger BRCA effect
Combination Therapy Shows Promise for Metastatic Prostate Cancer
This meta-analysis of 2343 men with HRR-altered metastatic prostate cancer found that adding a PARP inhibitor to an androgen-receptor signal…
A new combination of drugs may slow cancer growth for men with specific genetic markers, though it comes with a higher risk of severe side e…
PARP inhibitor maintenance improves progression-free survival in advanced ovarian cancer with HRD-positive status
PARP Inhibitors Show Benefit for Advanced Ovarian Cancer Patients
This network meta-analysis of 3,930 patients evaluated PARP inhibitor monotherapy and combination therapies for advanced ovarian, fallopian …
PARP inhibitor-based maintenance significantly improves progression-free survival for patients with advanced ovarian, fallopian tube, or per…
Multifaceted mechanisms including replication fork stabilization and epigenetic reprogramming drive PARP inhibitor resistance in ovarian cancer
New Strategies May Help Overcome Ovarian Cancer Treatment Resistance
This narrative review explores the mechanisms of resistance to PARP inhibitors in patients with advanced epithelial ovarian cancer. The auth…
Researchers are identifying specific biological mechanisms that cause ovarian cancer to resist PARP inhibitors, opening doors for new treatm…
BRCA1 or BRCA2 mutations correlate with improved survival and platinum sensitivity in ovarian cancer
BRCA Mutations Linked to Better Ovarian Cancer Survival
This systematic review examines the impact of BRCA1 and BRCA2 mutation status on treatment outcomes in ovarian cancer patients. The review f…
Women with ovarian cancer and BRCA mutations may live longer and respond better to certain treatments, a review finds.
Docetaxel and PARPi additions to ARPI and ADT improve progression-free survival in mHSPC
New data shows potential benefits for advanced prostate cancer patients
This network meta-analysis of 18,689 patients with metastatic hormone-sensitive prostate cancer (mHSPC) evaluated first-line systemic combin…
New data suggests that adding specific drugs to standard hormone therapy may help slow the growth of advanced prostate cancer.
Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC
New data shows specific drug combinations improve triple-negative breast cancer outcomes
This network meta-analysis of 7,683 patients with early-stage triple-negative breast cancer (TNBC) evaluated various neoadjuvant treatment r…
New data shows that adding specific drugs like pembrolizumab or bevacizumab to standard chemotherapy can improve response rates for early-st…
NLRP3 inflammasome modulates immune evasion and chemotherapy sensitivity in gynecological cancers
New research identifies a key driver in gynecological cancer cells
This mini-review examines the role of the NLRP3 inflammasome in ovarian, endometrial, and cervical cancers. It highlights how NLRP3 impacts …
A protein called NLRP3 helps certain cancers hide from the immune system, but it also plays a complex role in how tumors react to treatment.
Combination strategies using DNA damage response inhibitors aim to overcome resistance in pancreatic cancer
New combination strategies aim to treat pancreatic cancer more effectively
This systematic review evaluates DNA damage response (DDR) inhibitors, including monotherapy and combination regimens, for pancreatic cancer…
Combining different drugs could help overcome treatment resistance and reach more patients with pancreatic cancer.
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Review of bibliometric data shows growing research interest in macrophage polarization strategies for prostate cancer since 2015
Your Body's Immune Cells Could Fight Prostate Cancer Better
This bibliometric and visual analysis review examines publications related to macrophage polarization and activation in prostate cancer. The…
• Scientists reprogrammed immune cells to attack prostate tumors • Helps men with stubborn advanced prostate cancer • Still in early clinica…
Review of immunotherapy innovations for triple-negative breast cancer survival
New Hope for Tough-to-Treat Breast Cancer
This narrative review examines immunotherapy innovations, including immune checkpoint inhibitors and combination strategies, for patients wi…
This approach may change how doctors treat one of the hardest forms of breast cancer.
PARP inhibitors significantly improve progression-free survival in BRCA-mutated ovarian cancer patients
PARP Drugs Help BRCA Ovarian Cancer Patients Live Longer
This meta-analysis of 12 studies evaluated PARP inhibitor–based therapy in patients with BRCA-mutated ovarian cancer.
Women with BRCA-mutated ovarian cancer gain real survival time gains when using PARP inhibitors to delay cancer growth and stay cancer-free …
All PARP inhibitors Articles
- PARP plus ARSI improves rPFS in HRR-altered metastatic prostate cancer, with larger BRCA effect
- PARP inhibitor maintenance improves progression-free survival in advanced ovarian cancer with HRD-positive status
- Multifaceted mechanisms including replication fork stabilization and epigenetic reprogramming drive PARP inhibitor resistance in ovarian cancer
- BRCA1 or BRCA2 mutations correlate with improved survival and platinum sensitivity in ovarian cancer
- Docetaxel and PARPi additions to ARPI and ADT improve progression-free survival in mHSPC
- Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC
- NLRP3 inflammasome modulates immune evasion and chemotherapy sensitivity in gynecological cancers
- Combination strategies using DNA damage response inhibitors aim to overcome resistance in pancreatic cancer
- Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
- Review of bibliometric data shows growing research interest in macrophage polarization strategies for prostate cancer since 2015
- Review of immunotherapy innovations for triple-negative breast cancer survival
- PARP inhibitors significantly improve progression-free survival in BRCA-mutated ovarian cancer patients
- Precision oncology enables targeted therapies for gynecologic cancers, though acquired resistance remains a barrier